Greenwich LifeSciences, Inc. (GLSI) stock climbed Friday without any new company announcements, continuing the momentum from an update earlier in the week that detailed progress on its Phase 3 breast cancer vaccine trial.
The rally appears to be driven by a corporate update from earlier this week that outlined how the company is streamlining its FLAMINGO-01 clinical trial while positioning itself for potential partnerships. The update painted a picture of growing patient interest in GLSI-100, an immunotherapy designed to prevent breast cancer recurrence, and management's efforts to reduce risk and control costs as enrollment picks up steam.
Trial Expansion and Patient Demand
FLAMINGO-01 currently operates at roughly 140 active sites enrolling patients. Greenwich LifeSciences plans to activate 10 additional approved sites in 2026 and push further into European Union countries. What's interesting here is the shift in dynamics: investigator interest is increasingly being driven by actual patient demand rather than the other way around. Some sites are even reporting waitlists, which suggests genuine interest in this immunotherapy approach.
The company is also making operational changes designed to improve trial quality while cutting expenses. This includes bringing more clinical trial operations in-house and dropping its contract research organization for U.S. and global trial management. That's the kind of move that signals confidence in managing the complexity internally while keeping a tighter grip on costs.
Managing the Cash Burn
Management emphasized that its at-the-market equity facility is being used conservatively, aligned with the company's cash burn rate of about $7 million annually in recent years. While reported net losses look higher because of non-cash stock-based compensation, the actual operational cash usage has stayed relatively low. For the first three quarters of 2025, the burn rate held near that $7 million mark, supported by a lean organizational structure and deliberate cost-saving measures.
The FLAMINGO-01 Data Safety Monitoring Board met twice in 2025, most recently in December, and recommended continuing the study without modifications. Meanwhile, the Steering Committee met during SABCS 2025 and endorsed planned protocol changes pending regulatory approval. These modifications include expanding the study size, boosting enrollment rates, and using interim analyses to potentially adjust study parameters as data comes in.
GLSI Price Action: Greenwich LifeSciences shares were up 16.21% at $19.99 at the time of publication on Friday, marking a new 52-week high according to market data.
